Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors

被引:29
|
作者
Pontow, S [1 ]
Ratner, L [1 ]
机构
[1] Washington Univ, Sch Med, Dept Internal Med, Div Mol Oncol, St Louis, MO 63110 USA
关键词
D O I
10.1128/JVI.75.23.11503-11514.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type 1 (HIV-1) infection in vivo is dependent upon the interaction of the viral envelope glycoprotein gp120 with CC chemokine receptor 5 (CCR5) or CXC chemokine receptor 4 (CXCR4). To study the determinants of the gp120-coreceptor association, we generated a set of chimeric HIV-1 coreceptors which express all possible combinations of the four extracellular domains of CCR5 and CXCR4. Stable U87 astroglioma cell lines expressing CD4 and individual chimeric coreceptor proteins were tested against a variety of R5, X4, and R5X4 envelope glycoproteins and virus strains for their ability to support HIV-1-mediated cell fusion and infection, respectively. Each of the cell lines promoted fusion with cells expressing an HIV envelope glycoprotein, except for U87.CD4.5455, which presents the first extracellular loop (ECL1) and flanking sequences of CXCR4 in the context of CCR5. However, all of the chimeric coreceptors allowed productive infection by one or more of the viral strains tested. Viral phenotype was a predictive factor for the observed activity of the chimeric molecules; X4 and R5X4 HIV strains utilized a majority of the chimeras, while R5 strains were limited in their ability to infect cells expressing these chimeric molecules. The expression of CCR5 ECL2 within the CXCR4 backbone supported infection by an R5 primary isolate, but no chimeras bearing the N terminus of CCR5 exhibited activity with R5 strains. Remarkably, the introduction of any CXCR4 domain into the CCR5 backbone was sufficient to allow utilization by multiple X4 strains. However, critical determinants within ECL2 and/or ECL3 of CXCR4 were apparent for all X4 viruses upon replacement of these domains in CXCR4 with CCR5 sequences. Unexpectedly, chimeric coreceptor-facilitated entry was blocked in all cases by the presence of the CXCR4-specific inhibitor AMD3100. Our data provide proof that CCR5 contains elements that support usage by X4 viral strains and demonstrate that the gp120 interaction sites of CCR5 and CXCR4 are structurally related.
引用
收藏
页码:11503 / 11514
页数:12
相关论文
共 50 条
  • [21] Logistic Regression Classifiers in the Analysis of HIV-1 Use of CCR5 and CXCR4 Coreceptors
    Barros, Cesar
    Raposo, Leticia
    Nobre, Flavio
    XXVI BRAZILIAN CONGRESS ON BIOMEDICAL ENGINEERING, CBEB 2018, VOL 1, 2019, 70 (01): : 675 - 678
  • [22] Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans
    Juffermans, NP
    Verbon, A
    Olszyna, DP
    van Deventer, SJH
    Speelman, P
    van der Poll, T
    JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05): : 1813 - 1816
  • [23] Increased density of human immunodeficiency virus type 1 coreceptors CCR5 and CXCR4 on the surfaces of CD4+ T cells and monocytes of patients with Schistosoma mansoni infection
    Secor, WE
    Shah, A
    Mwinzi, PMN
    Ndenga, BA
    Watta, CO
    Karanja, DMS
    INFECTION AND IMMUNITY, 2003, 71 (11) : 6668 - 6671
  • [24] CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates
    Thompson, DAD
    Cormier, EG
    Dragic, T
    JOURNAL OF VIROLOGY, 2002, 76 (06) : 3059 - 3064
  • [25] Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4
    Lee, B
    Doranz, BJ
    Rana, S
    Yi, YJ
    Mellado, M
    Frade, JMR
    Martinez, C
    O'Brien, SJ
    Dean, M
    Collman, RG
    Doms, RW
    JOURNAL OF VIROLOGY, 1998, 72 (09) : 7450 - 7458
  • [26] Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1
    Hunt, Joshua S.
    Romanelli, Frank
    PHARMACOTHERAPY, 2009, 29 (03): : 295 - 304
  • [27] Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5
    Isaka, Y
    Sato, A
    Miki, S
    Kawauchi, S
    Sakaida, H
    Hori, T
    Uchiyama, T
    Adachi, A
    Hayami, M
    Fujiwara, T
    Yoshie, O
    VIROLOGY, 1999, 264 (01) : 237 - 243
  • [28] Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors
    Barin, F
    Brunet, S
    Brand, D
    Moog, C
    Peyre, R
    Damond, F
    Charneau, P
    Barre-Sinoussi, F
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02): : 322 - 327
  • [29] gp120 Envelope glycoproteins of human immunodeficiency viruses competitively antagonize signaling by coreceptors CXCR4 and CCR5
    Madani, N
    Kozak, SL
    Kavanaugh, MP
    Kabat, D
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) : 8005 - 8010
  • [30] Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: In vitro studies of mixed virus infections
    Rusconi, S
    Catamancio, SL
    Citterio, P
    Bulgheroni, E
    Croce, F
    Herrmann, SH
    Offord, RE
    Galli, M
    Hirsch, MS
    JOURNAL OF VIROLOGY, 2000, 74 (19) : 9328 - 9332